She will move if the results are solid.. starting from a low...

She will move if the results are solid.. starting from a low market cap and the synergy with existing and more up to date treatments is the key.Shes tightly held and in the multi billion dollar global hcv treatment market she will offer a competitive edge.HCV/HIV are still treated by a cocktail of drugs.

BIT225 was never a stand alone treatment and the prospect of HIV trials adds a little more excitement

Shes fairly priced with a diluted market cap of $15 mil pre results but is a boom/bust play and not without risk.Nothing to do but wait.GL holders